Literature DB >> 23866799

Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases.

Yang Zhao1, Heng Zhao, Dingzhong Hu, Limin Fan, Jianxin Shi, Wentao Fang.   

Abstract

BACKGROUND: Thymic squamous cell carcinomas are rare malignancies with limited information regarding results of surgery therapy. The objective of the current study was to evaluate their clinical and pathologic features and possible prognostic factors.
METHODS: From February 2003 to December 2010, 105 consecutive surgical patients were enrolled in this study with pathologic confirmed thymic squamous cell carcinoma in Shanghai Chest Hospital. Clinical and pathologic data were retrospectively reviewed. Survival analysis was performed using the Kaplan-Meier and log rank tests. Multivariate analysis was performed using the Cox regression model.
RESULTS: The squamous cell subtype made up 73.4% of the thymic carcinomas and 16.1% of total thymic tumors. Four patients (3.8%) presented with myasthenia gravis. The 5-year overall survival rate and the disease-free survival rate were 59.5% and 57.6%, respectively. On multivariate analysis, only the completeness of resection (hazard ratio 3.692; 95% confidence interval: 1.827 to 7.464; p=0.001) was found to have significant impact on overall survival. Completeness of resection (hazard ratio 2.361; 95% confidence interval: 1.226 to 4.547; p=0.010) and chemotherapy (hazard ratio 0.307; 95% confidence interval: 0.134 to 0.704; p=0.005) were associated with disease-free survival.
CONCLUSIONS: Complete resection not only predicts better overall survival but also extends disease-free interval after resection of thymic squamous cell carcinoma. Our results provide additional evidence supporting an alternative clinical stage specific for thymic carcinoma.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  13

Mesh:

Year:  2013        PMID: 23866799     DOI: 10.1016/j.athoracsur.2013.04.078

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  18 in total

1.  Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging.

Authors:  Anya M Litvak; Kaitlin Woo; Sara Hayes; James Huang; Andreas Rimner; Camelia S Sima; Andre L Moreira; Maria Tsukazan; Gregory J Riely
Journal:  J Thorac Oncol       Date:  2014-12       Impact factor: 15.609

2.  Robot-assisted en bloc anterior mediastinal mass excision with pericardium and adjacent lung for locally advanced thymic carcinoma.

Authors:  Hee Chul Yang; Garrett Coyan; Matthew Vercauteren; Neha Reddy; James D Luketich; Inderpal S Sarkaria
Journal:  J Vis Surg       Date:  2018-05-31

3.  Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma.

Authors:  Katsuhiro Okuda; Risa Oda; Ayumi Suzuki; Tsutomu Tatematsu; Hiroshi Haneda; Satoru Moriyama; Motoki Yano; Ryoichi Nakanishi
Journal:  Oncol Lett       Date:  2017-03-06       Impact factor: 2.967

4.  Thymic carcinoma patients with myasthenia gravis exhibit better prognoses.

Authors:  Wenya Li; Zhifeng Miao; Xudong Liu; Qigang Zhang; Lei Sun; Peiwen Li; Wenke Liu; Lin Zhang
Journal:  Int J Clin Oncol       Date:  2015-07-03       Impact factor: 3.402

5.  Concurrent thymic carcinoma and middle lobe syndrome.

Authors:  Xi Zheng; Yue Huang; Junhe Gou; Daxing Zhu; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  Elevated pretreatment serum lactate dehydrogenase level predicts inferior overall survival and disease-free survival after resection of thymic carcinoma.

Authors:  Qianwen Liu; Xiayu Fu; Xiaodong Su; Xin Wang; Yijun Zhang; Hong Yang; Yi Hu; Jing Wen; Jianhua Fu
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

7.  GAD1 expression and its methylation as indicators of malignant behavior in thymic epithelial tumors.

Authors:  Shiho Soejima; Kazuya Kondo; Mitsuhiro Tsuboi; Kyoka Muguruma; Bilguun Tegshee; Yukikiyo Kawakami; Koichiro Kajiura; Naoya Kawakita; Hiroaki Toba; Mitsuteru Yoshida; Hiromitsu Takizawa; Akira Tangoku
Journal:  Oncol Lett       Date:  2021-04-21       Impact factor: 2.967

8.  Treatment and prognosis of Masaoka stage 3 thymic carcinoma: a retrospective study of 32 cases.

Authors:  Yan Sun; Jinshi Liu; Xinmin Yu
Journal:  Onco Targets Ther       Date:  2015-04-06       Impact factor: 4.147

9.  Thymic Carcinomas and Second Malignancies: A Single-Center Review.

Authors:  Sunil S Badve; Rachel Dougherty; Michael Balatico; Kenneth A Kesler; Patrick Loehrer; Yesim Gökmen-Polar
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

10.  Adjuvant chemotherapy improves survival outcomes after complete resection of thymic squamous cell carcinoma: a retrospective study of 116 patients.

Authors:  Lanting Gao; Changlu Wang; Mina Liu; Wentao Fang; Changxing Lv; Xiaolong Fu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.